According to the research from the California University, San Francisco, human stem cells can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury - ALI.
Researchers have used human lungs that had been declined for transplantation. The aim was to determine whether stem cell therapy would be able to repair the damaged alveolar epithelium.
Scientists perfused the lungs with whole blood and ventilated with continuous positive airway pressure. The right middle lung was infused with endotoxin, which induced acute lung injury. Then they gave intravenously clinical grade human mesenchymal stem cells - hMSC.
It was found intravenous infusion of clinical grade cryo-preserved allogeneic hMSC were effective in restoring the capacity of the alveolar epithelium to resolve pulmonary edema when given after the establishment of E. coli endotoxin-induced acute lung injury in an ex vivo perfused human lung preparation. The infusion of human mesenchymal stem cells found place in the injured areas of the lung. It means the cells found their way from the bloodstream to the sites in the lung of injury.
Intravenous administration would be preferred in critically ill mechanically ventilated patients with ALI.
The results of the investigations suggested that the intravenous route would be ideal for potential clinical trials of hMSC for ALI - a syndrome of acute respiratory failure in critically ill patients.
It is needed to do more experiments testing the effect of hMSC against live bacterial induced lung injury in the perfused human lung.